An Alternate Future

We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.

First-in-class therapies to treat neurodegenerative disease

Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.

Our therapies

News

New Publication Demonstrates ATH434 is Neuroprotective

July 15, 2021July 15, 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas

Read More

Senior male researcher carrying out scientific research

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s

July 1, 2021July 15, 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the granting of a new composition o

Read More

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

June 23, 2021July 15, 2021

Highlights: Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its

Read More

Receive news from Alterity Therapeutics